CLINICAL TRIALS PROFILE FOR VABOMERE
✉ Email this page to a colleague
All Clinical Trials for vabomere
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Department of Health and Human Services | Phase 3 | 2014-11-20 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Melinta Therapeutics, Inc. | Phase 3 | 2014-11-20 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Phase 3 | 2014-11-20 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
NCT02168946 ↗ | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Completed | Department of Health and Human Services | Phase 3 | 2014-07-01 | Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae |
NCT02168946 ↗ | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Completed | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | Phase 3 | 2014-07-01 | Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae |
NCT02168946 ↗ | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Completed | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Phase 3 | 2014-07-01 | Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae |
NCT02687906 ↗ | Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections | Recruiting | Department of Health and Human Services | Phase 1 | 2016-07-01 | A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for vabomere
Condition Name
Clinical Trial Locations for vabomere
Trials by Country
Clinical Trial Progress for vabomere
Clinical Trial Phase
Clinical Trial Sponsors for vabomere
Sponsor Name
Sponsor Name for vabomere | |
Sponsor | Trials |
Department of Health and Human Services | 3 |
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | 3 |
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | 3 |
[disabled in preview] | 2 |
This preview shows a limited data set Subscribe for full access, or try a Trial |